Andreea Calugareanu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andreea Calugareanu has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Jean-David Bouaziz
Université Paris Cité, INSERM U1342, Institut de Recherche Saint‐Louis Paris France
9 shared publications - Maxime Battistella
INSERM U1342 Saint-Louis Research Institute , Paris
6 shared publications - Hélène Le Buanec
INSERM U976, Hôpital Saint-Louis, Paris, France
5 shared publications - Marie Jachiet
Dermatology Department Saint Louis Hospital Paris France
5 shared publications - Adèle de Masson
Service de Dermatologie Hôpital Saint Louis, Assistance Publique‐Hôpitaux de Paris (AP‐HP) Paris France
4 shared publications - Charles Cassius
Department of Dermatology, Hôpital Saint‐Louis, AP‐HP; INSERM U1342 Université Paris Cité Paris France
4 shared publications
Latest Publications
- Open Access
- 29 May 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (10) , 1832-1843
Lichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation
Background: Chronic cutaneous graft‐versus‐host disease (ccGVHD) is a debilitating complication of allogeneic haematopoietic stem cell transplantation, manifesting as either sclerotic or lichenoid eruptions (lGVHD). Although frequent, the pathogenesis of lGVHD remains mainly unknown and represents a therapeutic challenge.Objectives: This study aims to decipher the immunological mechanisms underlying lichenoid GVHD and to evaluate the effect of blocking the Type I interferons (IFN‐I) pathway in a mice model of ccGVHD on local inflammation.Methods: First, we performed single‐cell gene expression analysis (scRNA‐Seq) of human lGVHD skin samples (n = 3) compared with healthy control (n = 4) and analysed the distribution and inflammatory signatures of immune cells. Results were confronted with bulk‐RNA‐Seq data of an independent cohort of lGVHD (n = 8) previously published by our group to compare the predicted immune population within lGVHD skin through deconvolution analyses. The IFN‐I score was assessed through quantitative PCR on lGVHD lesions (n = 13) compared with HC (n = 10). Secondly, we analysed publicly available skin microarray data from a mouse model of ccGVHD, in which allografted mice were treated with an anti‐IFNAR1 antibody targeting the Type I interferon receptor.Results: ScRNA‐Seq analysis of human immune cells revealed a strong Type I and II interferons signature in lGVHD skin, along with an increased expression of Th2/Th17 and activation markers in T cells and macrophages, respectively. Consistent with our human data, murine skin GVHD samples were characterized by interferon and allograft inflammatory responses, which were greatly prevented by early infusions of anti‐IFNAR1 antibody after allograft. Bioinformatic analyses highlighted interferons, along with Th2 and Th17 markers, as putative key regulators in mice skin inflammation that were also diminished or abrogated consequently to early anti‐IFNAR1 antibody infusions.Conclusions: Together, our data suggests that interferon pathways, and in particular Type I via IFNAR1, may be promising therapeutic targets for the treatment of lichenoid chronic GVHD.
- 29 May 2025
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (10) , 1832-1843
Open AccessLichenoid graft‐versus‐host disease shows a high interferon score, with IFNAR1 inhibition preventing skin inflammation
Background: Chronic cutaneous graft‐versus‐host disease (ccGVHD) is a debilitating complication of allogeneic haematopoietic stem cell transplantation, manifesting as either sclerotic or lichenoid eruptions (lGVHD). Although frequent, the pathogenesis of lGVHD remains mainly unknown and represents a therapeutic challenge.Objectives: This study aims to decipher the immunological mechanisms underlying lichenoid GVHD and to evaluate the effect of blocking the Type I interferons (IFN‐I) pathway in a mice model of ccGVHD on local inflammation.Methods: First, we performed single‐cell gene expression analysis (scRNA‐Seq) of human lGVHD skin samples (n = 3) compared with healthy control (n = 4) and analysed the distribution and inflammatory signatures of immune cells. Results were confronted with bulk‐RNA‐Seq data of an independent cohort of lGVHD (n = 8) previously published by our group to compare the predicted immune population within lGVHD skin through deconvolution analyses. The IFN‐I score was assessed through quantitative PCR on lGVHD lesions (n = 13) compared with HC (n = 10). Secondly, we analysed publicly available skin microarray data from a mouse model of ccGVHD, in which allografted mice were treated with an anti‐IFNAR1 antibody targeting the Type I interferon receptor.Results: ScRNA‐Seq analysis of human immune cells revealed a strong Type I and II interferons signature in lGVHD skin, along with an increased expression of Th2/Th17 and activation markers in T cells and macrophages, respectively. Consistent with our human data, murine skin GVHD samples were characterized by interferon and allograft inflammatory responses, which were greatly prevented by early infusions of anti‐IFNAR1 antibody after allograft. Bioinformatic analyses highlighted interferons, along with Th2 and Th17 markers, as putative key regulators in mice skin inflammation that were also diminished or abrogated consequently to early anti‐IFNAR1 antibody infusions.Conclusions: Together, our data suggests that interferon pathways, and in particular Type I via IFNAR1, may be promising therapeutic targets for the treatment of lichenoid chronic GVHD.
- 27 December 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (6)
Mycobacterium chelonae cutaneous infections unrelated to invasive procedures: A multicentre retrospective case series
- 27 December 2024
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 39 (6)
Mycobacterium chelonae cutaneous infections unrelated to invasive procedures: A multicentre retrospective case series
- 30 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2525-2529.e5
Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing
- 30 May 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (12) , 2525-2529.e5
Transcriptomic Landscape of Prurigo Nodularis Lesional Skin CD3+ T Cells Using Single-Cell RNA Sequencing
- 24 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2078-2082.e4
Exploring the Nonlymphocytic Cutaneous Microenvironment in Advanced Cutaneous T-Cell Lymphomas using Single-Cell RNA Sequencing
- 24 April 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (10) , 2078-2082.e4
Exploring the Nonlymphocytic Cutaneous Microenvironment in Advanced Cutaneous T-Cell Lymphomas using Single-Cell RNA Sequencing
- 5 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (5) , 711-721.e7
IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis
- 5 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (5) , 711-721.e7
IL-4/IL-13 Inhibitors for Atopic Dermatitis Induce Psoriatic Rash Transcriptionally Close to Pustular Psoriasis
- 13 August 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (12) , E1071-E1072
Dramatic response to dupilumab in papular amyloidosis
- 13 August 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (12) , E1071-E1072
Dramatic response to dupilumab in papular amyloidosis
- Open Access
- 4 May 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (9) , 2805-2811
RNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea
Cutaneous involvement of chronic graft-versus-host disease (cGVHD) has a wide range of manifestations including a lichenoid form with a currently assumed mixed Th1/Th17 signature and a sclerotic form with Th1 signature. Despite substantial heterogeneity of innate and adaptive immune cells recruited to the skin and of the different clinical manifestations, treatment depends mainly on the severity of the skin involvement and relies on systemic, high-dose glucocorticoids alone or in combination with a calcineurin inhibitor. We performed the first study using RNA sequencing to profile and compare the transcriptome of lichen planus cGVHD (n = 8), morphea cGVHD (n = 5), and healthy controls (n = 6). Our findings revealed shared and unique inflammatory pathways to each cGVHD subtype that are both pathogenic and targetable. In particular, the deregulation of IFN signaling pathway was strongly associated with cutaneous cGVHD, whereas the triggering receptor expressed on myeloid cells 1 pathway was found to be specific of lichen planus and likely contributes to its pathogenesis. The results were confirmed at a protein level by performing immunohistochemistry staining and at a transcriptomic level using real-time quantitative polymerase chain reaction.
- 4 May 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (9) , 2805-2811
Open AccessRNA sequencing of chronic GVHD skin lesions defines shared and unique inflammatory pathways characterizing lichen planus and morphea
Cutaneous involvement of chronic graft-versus-host disease (cGVHD) has a wide range of manifestations including a lichenoid form with a currently assumed mixed Th1/Th17 signature and a sclerotic form with Th1 signature. Despite substantial heterogeneity of innate and adaptive immune cells recruited to the skin and of the different clinical manifestations, treatment depends mainly on the severity of the skin involvement and relies on systemic, high-dose glucocorticoids alone or in combination with a calcineurin inhibitor. We performed the first study using RNA sequencing to profile and compare the transcriptome of lichen planus cGVHD (n = 8), morphea cGVHD (n = 5), and healthy controls (n = 6). Our findings revealed shared and unique inflammatory pathways to each cGVHD subtype that are both pathogenic and targetable. In particular, the deregulation of IFN signaling pathway was strongly associated with cutaneous cGVHD, whereas the triggering receptor expressed on myeloid cells 1 pathway was found to be specific of lichen planus and likely contributes to its pathogenesis. The results were confirmed at a protein level by performing immunohistochemistry staining and at a transcriptomic level using real-time quantitative polymerase chain reaction.
- Open Access
- 22 December 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (4) , E263-E265
Extensive cutaneous lichen planus triggered by viral vector COVID‐19 vaccination (ChAdOx1 nCoV‐19)
- 22 December 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (4) , E263-E265
Open AccessExtensive cutaneous lichen planus triggered by viral vector COVID‐19 vaccination (ChAdOx1 nCoV‐19)
- Open Access
- 1 December 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1176-1185
Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*
SummaryBackground. The outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 in
- 1 December 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1176-1185
Open AccessType I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*
SummaryBackground. The outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 in
- 28 November 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (4) , E308-E310
Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus
- 28 November 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (4) , E308-E310
Clinical efficacy of selective JAK1 inhibition and transcriptome analysis of chronic discoid lupus erythematosus